SANUWAVE Health

Q1 FY2026 EarningsQ2 FY26 preliminary revenue is expected between $9.6M and $9.8M, exceeding the high end of revised guidance ($8.5M–$9.5M). Total revenue decreased 3–5% YoY from $10.1M in Q2 FY25 due to capital equipment sales headwinds and secondary market competition for Ultramist systems. Conversely, consumable applicator sales achieved all-time records in both units and revenue, signaling strong adoption of the recurring 'razor-razorblade' model. Management introduced a trade-in program for used systems to mitigate secondary market impact.